Delva Deauna‐Limayo

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

John C. Byrd, John M. Pagel, Farrukh T. Awan et al. · Blood · 2014 · 71 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

Pavan S. Reddy, Delva Deauna‐Limayo, James D. Cook et al. · Annals of Hematology · 2004 · 64 citations

Medicine, Hematology, Immunology +7

<scp>CD</scp>20‐positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab

Min Yan, Zhaoming Dong, Frank Zhao et al. · European Journal Of Haematology · 2014 · 38 citations · Full text

Medicine, Hematology, Oncology +12

Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis

Pannaga Malalur, Manas Agastya, Sandhya Wahi‐Gururaj et al. · Cancer Medicine · 2021 · 14 citations · Full text

Public Health, Health Behavior, Oncology +17

Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study

Delva Deauna‐Limayo, Omar S. Aljitawi, Siddhartha Ganguly et al. · Journal of Oncology Pharmacy Practice · 2013 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +17